Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) and Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.
Insider and Institutional Ownership
79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Jasper Therapeutics has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jasper Therapeutics | N/A | N/A | -$64.46 million | ($6.20) | -3.84 |
| Finch Therapeutics Group | $107,000.00 | 37.82 | -$74.75 million | ($47.67) | -0.05 |
Jasper Therapeutics has higher earnings, but lower revenue than Finch Therapeutics Group. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Jasper Therapeutics and Finch Therapeutics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jasper Therapeutics | N/A | -63.21% | -55.07% |
| Finch Therapeutics Group | N/A | -136.63% | -57.40% |
Analyst Recommendations
This is a breakdown of recent recommendations for Jasper Therapeutics and Finch Therapeutics Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jasper Therapeutics | 0 | 0 | 8 | 0 | 3.00 |
| Finch Therapeutics Group | 0 | 0 | 0 | 0 | N/A |
Jasper Therapeutics currently has a consensus price target of $64.17, suggesting a potential upside of 169.38%. Given Jasper Therapeutics’ higher possible upside, equities analysts plainly believe Jasper Therapeutics is more favorable than Finch Therapeutics Group.
Summary
Jasper Therapeutics beats Finch Therapeutics Group on 8 of the 11 factors compared between the two stocks.
About Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
